PUBLISHER: The Business Research Company | PRODUCT CODE: 1763068
PUBLISHER: The Business Research Company | PRODUCT CODE: 1763068
Comirnaty (tozinameran) is an mRNA-based vaccine developed for the prevention of COVID-19. It uses lipid nanoparticles to deliver mRNA, instructing cells to produce a protein resembling the SARS-CoV-2 spike protein, which triggers an immune response. This helps prevent COVID-19 infection and reduces the severity of the disease, including severe outcomes like hospitalization and death.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main formulations for comirnaty include conventional and lipid nanoparticle-based formats, designed to enhance the delivery and efficacy of the vaccine. The primary indications for this vaccine are COVID-19 prevention and treatment. Comirnaty works by utilizing mRNA that encodes for the spike protein and other key viral components, enabling a precise immune response. It is used in various healthcare settings, including hospitals and clinics, and is intended for adults, children aged 12 and older, and, in some cases, children under 12, ensuring broad accessibility for diverse age groups.
The comirnaty (tozinameran) market research report is one of a series of new reports from The Business Research Company that provides comirnaty (tozinameran) market statistics, including comirnaty (tozinameran) industry global market size, regional shares, competitors with a comirnaty (tozinameran) market share, detailed comirnaty (tozinameran) market segments, market trends and opportunities, and any further data you may need to thrive in the comirnaty (tozinameran) industry. This comirnaty (tozinameran) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The comirnaty (tozinameran) market size is expected to see exponential growth in the next few years. It will grow to $17,976.3 million in 2029 at a compound annual growth rate (CAGR) of 21%. The growth in the forecast period can be attributed to authorization for pediatric use, demand for variant-specific vaccines, increased vaccine accessibility in low-income regions, increasing private sector vaccine procurement, and emerging therapeutic applications of mRNA technology. Major trends in the forecast period include growing focus on mRNA platform innovations, integration of vaccine production with AI-driven analytics, increasing competition from next-generation vaccines, focus on sustainability in vaccine production, and advancements in needle-free vaccine delivery methods.
The increasing prevalence of infectious diseases is expected to significantly drive the growth of the comirnaty (tozinameran) market. Infectious diseases, caused by pathogens like bacteria, viruses, fungi, or parasites, are spreading more due to factors such as global travel, urbanization, climate change, and inadequate healthcare access. Comirnaty (tozinameran) plays a crucial role in controlling infectious diseases, especially COVID-19, by leveraging mRNA technology to provide effective protection. It helps reduce transmission rates, prevent severe cases, and minimize hospitalizations. For instance, the UK Health Security Agency reported a nearly sevenfold increase in measles cases in 2023, which highlights the growing need for effective vaccines like Comirnaty to combat infectious diseases. As a result, the rising prevalence of infectious diseases is driving the demand for comirnaty.
Rising trends in personalized medicine are expected to propel the growth of the comirnaty market. Personalized medicine tailors treatments based on individual characteristics such as genetic makeup, lifestyle, and environment to improve treatment outcomes. This approach is growing due to advancements in genomics, precision diagnostics, and the demand for more targeted therapies. Comirnaty, with its mRNA technology, supports this trend by providing a flexible vaccine platform that can be rapidly adapted to meet individual genetic profiles. In 2022, the FDA approved personalized medicines for 34% of new drugs, underscoring the increasing adoption of personalized medicine. Thus, the rise of personalized medicine will further fuel the growth of the comirnaty market.
A key trend in the comirnaty market is the development of innovative products such as the bivalent mRNA COVID-19 vaccine, which provides enhanced protection against both the original virus and emerging variants like Omicron. Bivalent vaccines are designed to target both the original SARS-CoV-2 strain and specific variants, improving immune response and offering broader protection. In December 2023, the Therapeutic Goods Administration in Australia approved Pfizer's COMIRNATY Original/Omicron BA.4-5 COVID-19 Vaccine as a booster for individuals aged 5 years and older. This approval reflects the growing trend of adapting vaccines to target evolving strains, ensuring continued effectiveness against emerging COVID-19 variants and strengthening global public health resilience.
Major players operating in the comirnaty (tozinameran) market are Pfizer Inc.; BioNTech SE
North America was the largest region in the comirnaty (tozinameran) market in 2024. The regions covered in comirnaty (tozinameran) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the comirnaty (tozinameran) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The comirnaty (tozinameran) market consists of sales of multidose vials, single-dose prefilled syringes, and combination products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Comirnaty (Tozinameran) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on comirnaty (tozinameran) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for comirnaty (tozinameran) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The comirnaty (tozinameran) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.